Boryung Rebounds After Announcing Physical Split-Off, Rising More Than 4% Early in the Session [Stock NOW]

[Financial News] Boryung is rebounding after announcing that it will carry out a physical split-off of its prescription-drug (ETC) sales and marketing division to establish Boryung Pharma Solution.
As of 9:26 a.m. on the 16th, Boryung was trading at 8,960 won, up 370 won, or 4.31%, from the previous trading day. The stock closed at 8,660 won the previous day, down 6.68%, after news of the physical split-off emerged. The rise is also being interpreted as a partial reversal of the sharp decline that followed the split-off announcement.
At a board meeting on the 15th, Boryung approved a physical split-off to establish Boryung Pharma Solution, which will be dedicated to prescription-drug sales and marketing. Following a shareholders’ meeting next month, the new entity is scheduled to launch on January 4 next year as a wholly owned subsidiary in which Boryung will hold a 100% stake.
After the split-off, the surviving company, Boryung, will focus on production, research and development (R&D), and space and life sciences research. Boryung Pharma Solution will handle commercial functions, including prescription-drug sales and marketing, business development, and distribution.
Through the move, Boryung aims to strengthen its sales expertise and achieve a domestic pharmaceutical market share of more than 10%.
A key point drawing market attention is the company’s stated intention to prevent concerns about the creation of a listed subsidiary following the physical split-off. Boryung said it will keep the new entity unlisted and does not plan to apply for a preliminary listing review within five years of the split-off. Its articles of incorporation will also be amended to require approval from the parent company’s shareholders’ meeting for any future IPO plans.
Boryung plans to expand its product portfolio by adding 26 proprietary products and 16 externally sourced products by 2030. The strategy is understood as an effort to specialize its commercial capabilities, from product acquisition to sales, by separating the sales and marketing functions into a standalone entity.

[email protected] Kang Jung-mo Reporter